Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

Fig. 1

Antitumor effects of TINO in glioma cell models: comparison with BDM and SAHA alone or in combination. a Representative crystal violet stain assay performed in U87MG cells. b IC50 values for temozolomide (TMZ) in different glioma and stem-like cells. c IC50 values for Bendamustine (BDM) in different glioma and stem-like cells. d IC50 values for tinostamustine (TINO) in different glioma and stem-like cells. In b, c, and d were added two markers: a red line showing the pharmacologically active concentration measured at the blood peak in humans for temozolomide (35 μM) and bendamustine (20 μM) as well as in brains of mice for tinostamustine (11.2 μM in the CNS after single i.v. bolus injection of 40 mg/kg, Huan Tun and collaborators manuscript submitted) and a dashed blue line indicating the in vitro cell sensitivity/resistance to the drugs. e Comparison on BDM and combination treatments using a fixed nontoxic dose of SAHA (200 nM) and increasing concentrations of BDM in U87MG, U251, A172, and T98G cell lines. f Histone deacetylase activity: comparison of inhibitory effects of SAHA and TINO. Single results are representative of three different experiments performed in triplicate

Back to article page